| Summary: | Aim: Many
epidemiological studies have found a high
incidence of depression and anxiety in people with epilepsy. Duloxetine is a selective
inhibitor of serotonin and norepinephrine reuptake (SNRI) and commonly prescribed in a patient with major depressive
disorder. The aim of this study was to investigate
the effect of duloxetine on the WAG/Rij rat in an experimental rat model
of absence-epilepsy.
Methods: WAG/Rij
rats were randomly assigned into 5 groups with 7 animals in each group. Tripolar
electrodes were placed on the skull to
perform electrocorticography (ECoG) evaluation. Then, following the recovery
period, ECoGs were recorded at 09:00 am for 3 hours every day. Subsequently, duloxetine (1, 5, 10
and 30 mg/kg) was injected
intraperitoneally (i.p). After
the treatment program, ECoG recordings were taken for 3 hours. And then all
animal anxiety-like behavior by using the
behavioral test, open field test (OFT) was performed after duloxetine (1,5,10
and 30 mg/kg) treatment. The total number and
the total duration of the spike-wave
discharges (SWDs) were
calculated offline. The
number of squares crossed (locomotor activity) and the duration of grooming
episodes were analyzed in OFT.
Results: The doses of duloxetine (1 mg/kg) did not alter ECoG and OFT parameters. The 5, 10 and 30 mg/kg doses of duloxetine decreased the total number and the total duration of
SWDs, (p lt;0.05) and increased the number of squares crossed when
compared to with control group (p lt;0.05) without changing duration of
grooming episodes (p gt; 0.05). Intraperitoneal administering of 1 mg/kg
duloxetine did not show any statistically
significant change in regard to the number and duration of SWDs.
Conclusions: In the present study, duloxetine reduce
dose-dependent absences-like seizures and
anxiety-like behavior.
|
|---|
